NHSBCSP - guidelines Phil Quirke. Why guidelines To meet the needs of the programme To improve outcomes To increase the knowledge base and evolve pathology.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Local Improvement following National Clinical Audit The View from a National Clinical Audit Provider – the Health & Social Care Information Centre.
Bowel Cancer screening programme The Facts Third most common Cancer in the UK. The Second most common cause of cancer deaths in the UK (approx 16,100.
Polyps – Where do they come from and what do you do with them?!
Colorectal Cancer Screening and Surveillance FDA Advisory Committee March, 2002 David Lieberman MD Chief, Division of Gastroenterology Oregon Health Sciences.
Role of colonoscopy in the treatment of malignant polyps Pathology of malignant colorectal polyps Assessing the risk of residual disease post-polypectomy.
Pathology in the UK Bowel Cancer Screening Programmes Frank Carey (Dundee)
The Adenoma/Carcinoma Sequence in the Colon
Surveillance colonoscopy after polypectomy – how frequent? Dr Chu Ming Leong Tuen Mun Hospital 1.
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007.
Multitarget Stool DNA Testing for Colorectal-Cancer Screening NEJM April 3, 2014 Vol 3 Imperiale, T.F. et al Presented by Melissa Spera, MD.
Joint Hospital Surgical Grand Round 19 June 2004.
Wilson and Jungner Criteria for Screening 1968
Reporting and Management of Early stage Colorectal Cancer Frank Carey Dundee.
Colorectal cancer Khayal AlKhayal MD,FRCSC
NHS Breast Screening Programme (NHSBSP) – Forrest report To detect early, non-palpable disease in WOMEN Mammogram Every 3 years 50 and over (47-73.
West Midlands Cancer Intelligence Unit NHSBSP Surgical QA Data for the Year of Screening 1 April 2002 to 31 March 2003 Dr Gill Lawrence and Professor Jan.
Bowel Screening in Scotland – Current Challenges and Possible Solutions Prof. Bob Steele Ninewells Hospital, University of Dundee.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
Bowel Cancer Alex Hill. Why screen for bowel cancer?  Bowel cancer causes deaths per yr  It may be detected at asymptomatic stage by simple, safe.
Ethical issues and cancer screening. Efficacy The extent to which a specific intervention, procedure, regimen, or service produces a beneficial result.
SYNOPSIS OF THE PROTOCOL Title: Pregnancy Associated Breast Cancer (PABC); Prospective Data Registry in Saudi Arabia Sponsor: Oncology Department, King.
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Not for reproduction IT Infrastructure NHS BCSP Julietta Patnick November 2007.
Colonoscopy; Surveillance Indications
TREATMENT OF LARGE AND GIANT COLORECTAL POLYPS IN THE REAL WORLD UEGW, PARIS, 2007 Association pour le Dépistage du Cancer colorectal dans le Haut-Rhin.
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Results and cost of a population-based biennial faecal occult blood colorectal cancer screening program Bernard DENIS, Philippe PERRIN, Jean François VIES,
Handling difficult cases and possible referral service Professor Neil A Shepherd Gloucester, UK NHSBCSP Pathology Day, London, November 21, 2007.
Population Screening for Colorectal Cancer - update of evidences
Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based fecal occult blood testing: a population-based controlled trial.
SETTING UP THE SERVICE BY LYNN TOBIN. HOW DID WE GET HERE? ABUNDENCE OF EVIDENCE PROVIDING JUSTIFICATION FOR BOWEL CANCER SCREENING.
Robert E. Schoen, MD MPH Associate Professor of Medicine and Epidemiology Division of Gastroenterology University of Pittsburgh Organizing Colorectal Cancer.
Cheshire & Merseyside Bowel Cancer Screening Programme April 2008.
Colonic cancer screening in high risk groups
Sessile Serrated Adenomas: A Case Presentation Kevin Witt, PGY3 Justin Whitt, MD IU Health Ball Memorial Family Medicine Residency.
Senior Statistician Per-Henrik Zahl, MA MD PhD
MALIGNANT POLYPS DURING THE FIRST THREE SCREENING ROUNDS ( ) FOR COLON-RECTAL CANCER (CRC) IN A NORTH-EASTERN SANITARY DISTRICT (ULSS-1 VENETO).
Do all colorectal polyps require pathological examination? Aim To assess whether it is possible to omit the pathological examination of some polyps without.
National Oesophago–Gastric Cancer Audit  This slide set is designed to ◦Summarise the main audit findings for presentation at local MDT meetings.
CT Colonography vs Colonoscopy for the Detection of Advanced Neoplasia David H. Kim, M.D., Perry J. Pickhardt, M.D., Andrew J. Taylor, M.D., Winifred K.
Cheshire & Merseyside Bowel Cancer Screening Programme April 2008.
Colorectal Cancer Screening Implementation of a public health programme An Expert Group on Colorectal Cancer Screening Cancer Society of Finland, Finnish.
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
First results of a pilot population-based faecal occult blood colorectal cancer screening program B. DENIS, P. PERRIN, J.F. EBELIN, P. WEBER, E. KALTENBACH,
Insert name of presentation on Master Slide Bowel Screening in Welsh Prisons Hayley Heard Head of Programme.
Guidelines for depression in palliative care WP 3.2 : EPCRC : Trondheim Irene Higginson, Alison Evans, Matthew Hotopf.
The Malignant Polyp Handout Version Hans Elzinga, MD Program Director- Advanced Procedures in Family Medicine Fellowship Salud Family Health Center-Longmont,
Measurement of SM invasion depth by ‘Committee of Management for sm Carcinoma Project’ of the Japanese Society for Cancer of the Colon and Rectum J Gastroenterol.
Am J Gastroenterol 2012; 107:1213– June 2012 R3. 김동희 /prof. 이창균.
FIT Programme (Faecal Immunohistochemical Test)
Cancer prevention and early detection
Public Health England leads the NHS Screening Programmes
Oesophago–Gastric Cancer
Underwriting Breast Cancer
National Oesophago–Gastric Cancer Audit 2015.
Bowel cancer screening update GP education event 28 Nov 2017
Jasper Vleugels PhD-student AMC
Repeat Colonoscopy Recommendations
BOWEL CANCER SCREENING 11/7/18
Reporting in CRC screening
Low Rates of Cancer or High-Grade Dysplasia in Colorectal Polyps Collected From Computed Tomography Colonography Screening  Perry J. Pickhardt, Kendra.
Colorectal Cancer Cancer Alliance Work
Public Health England leads the NHS Screening Programmes
Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer  Douglas K. Rex,
SYNOPSIS OF THE PROTOCOL
Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes Mammography screening.
Presentation transcript:

NHSBCSP - guidelines Phil Quirke

Why guidelines To meet the needs of the programme To improve outcomes To increase the knowledge base and evolve pathology practice

Faecal occult blood screening To determine the importance of the primary pathology found Predicting metachronous disease and follow up Are we missing important groups

FOB Haut-Rhin Denis et al 710,000 pop 36% HGD (4.6% in situ) 2.7% invasive 42.9% >1cm 80.3% adenomas 68.7% T 24.6% TV 2.5% V 4.2% Serrated Gut Nov Scottish pilot NHSBCSP 1M pop each 12% HGD (7% Coventry) 43.5% 6+mm 77.2% adenomas Definitely an issue about grading dysplasia more work needs to be done on adenoma types

Flexisigmoidoscopy/colonoscopy screening Primary pathology Predict synchronous disease Predict metachronous disease and follow up Are we missing important groups

FS & colonoscopy vs FOB Flexisigmoidoscopy/colonoscopy find smaller less advanced lesions (UK FS trial) –HGD 1% –>1cm 3-4% –Advanced adenoma rates 3-7% (agrees with German colonoscopy study Brenner Gut ) FOB larger, more dysplastic lesions –HGD 7-36% –>6mm 43.5% UK NHS >1cm France 43%, Nottingham trial 88%

Consistency between programmes Consistent with F/S guidelines Generated using groups that overlapped between the pilots and the F/S trial F/S Williams/Quirke Pilot FOB Carey/Neubold Additional experts Shepherd/Warren

Consistency with College and other bodies Involved cancer committee of College and colorectal guidelines and ACGB&I Williams/Quirke BSG pathology committee Warren BDIAP Shepherd Scotland - Carey Wales - Williams

Whats important?

Currently Size - increased risk of malignancy Type - increased risk of malignancy, further investigation Dysplasia - increasing aggressiveness Invasion - prognosis and further treatment

Need to: Determine reproducibility of criteria in routine practice Is it worth doing? Can we improve it?

Need to: Collect all data –All screen detected polyps –All screen detected cancers –Computerise –Accumulate follow up –Analyse Would also want all MDS’s for all CRC’s via registries –? Mandatory in new cancer plan

Looking for: New features that may be important Discard old non reproducible ones Derive new definitions? Compare conflicting methods –Haggitt –Kikuchi - level of invasion –Ueno - classification by depth microns Confirm importance of site

Mandatory for participants: Fill out and return pathollogy proforma on each case Fill out and return College minimum dataset on each screen detected cancer case - 100% EQA participation

Proforma

Feedback on: Polyp form –Ease of use –Issues IT systems EQA

Organisation NHSBCSP Julietta Patnick NHSBCSP pathology committee: –Quirke (Chair),Williams, Carey (QA), Warren, Shepherd (expert opinions),Mapstone (EQA) Regional leads England 10 including above Local screening lead Participating consultants

Meetings Main committee twice a year Once a year with regional leads –Policy –QA –EQA Once a year with participants –Proposed changes –EQA discussion

Web page

Summary Guidelines needed Consistent between types of screening Minimise variability –Invasion –Size –High grade dysplasia Electronic EQA being tested

Summary Will generate the largest bank of data on screening in the world Will save lives!

Flexisigmoidoscopy detection rates vary between observers

Flexisigmoidoscopy adenoma detection rates vary between studies